XLRN Stock Overview
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.
No risks detected for XLRN from our risk checks.
Acceleron Pharma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$178.75|
|52 Week High||US$189.99|
|52 Week Low||US$108.82|
|1 Month Change||3.62%|
|3 Month Change||46.35%|
|1 Year Change||57.43%|
|3 Year Change||252.84%|
|5 Year Change||370.64%|
|Change since IPO||794.20%|
Recent News & Updates
Merger Arbitrage Mondays: Merck Acquires Acceleron For $10.8 Billion
Merck acquires Acceleron for $180 per share in cash. Amicus Therapeutics to launch a genetic medicine company, Caritas Therapeutics through a business combination agreement with ARYA Sciences Acquisition Corp IV. Five9 and Zoom Video Communications mutually terminate their merger agreement.
|XLRN||US Biotechs||US Market|
Return vs Industry: XLRN exceeded the US Biotechs industry which returned 8.5% over the past year.
Return vs Market: XLRN exceeded the US Market which returned 28.1% over the past year.
|XLRN Average Weekly Movement||4.5%|
|Biotechs Industry Average Movement||8.6%|
|Market Average Movement||5.9%|
|10% most volatile stocks in US Market||15.1%|
|10% least volatile stocks in US Market||2.2%|
Stable Share Price: XLRN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: XLRN's weekly volatility (4%) has been stable over the past year.
About the Company
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia. The company is also developing Sotatercept, an activin receptor type IIA fusion protein, for the treatment of patients with pulmonary arterial hypertension; ACE-1334, a pulmonary therapeutic candidate that is in Phase I clinical trials; and luspatercept-aamt for non-transfusion-dependent beta-thalassemia patients and lower-risk myelodysplastic syndrome patients.
Acceleron Pharma Fundamentals Summary
|XLRN fundamental statistics|
Is XLRN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|XLRN income statement (TTM)|
|Cost of Revenue||US$230.40m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-4.17|
|Net Profit Margin||-226.00%|
How did XLRN perform over the long term?See historical performance and comparison
Is Acceleron Pharma undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: XLRN ($178.75) is trading below our estimate of fair value ($479.84)
Significantly Below Fair Value: XLRN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: XLRN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: XLRN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate XLRN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: XLRN is overvalued based on its PB Ratio (15.2x) compared to the US Biotechs industry average (3x).
How is Acceleron Pharma forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XLRN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: XLRN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: XLRN's is expected to become profitable in the next 3 years.
Revenue vs Market: XLRN's revenue (49.2% per year) is forecast to grow faster than the US market (10.2% per year).
High Growth Revenue: XLRN's revenue (49.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: XLRN is forecast to be unprofitable in 3 years.
How has Acceleron Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: XLRN is currently unprofitable.
Growing Profit Margin: XLRN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: XLRN is unprofitable, and losses have increased over the past 5 years at a rate of 20.9% per year.
Accelerating Growth: Unable to compare XLRN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XLRN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (14%).
Return on Equity
High ROE: XLRN has a negative Return on Equity (-35.49%), as it is currently unprofitable.
How is Acceleron Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: XLRN's short term assets ($696.6M) exceed its short term liabilities ($57.4M).
Long Term Liabilities: XLRN's short term assets ($696.6M) exceed its long term liabilities ($12.3M).
Debt to Equity History and Analysis
Debt Level: XLRN is debt free.
Reducing Debt: XLRN has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: XLRN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if XLRN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Acceleron Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate XLRN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate XLRN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if XLRN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if XLRN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of XLRN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Habib Dable (52 yo)
Mr. Habib J. Dable has been the Chief Executive Officer, President and Director at Acceleron Pharma Inc. since joining on December 1, 2016. Mr. Dable served as the President of Bayer HealthCare Pharmaceuti...
CEO Compensation Analysis
Compensation vs Market: Habib's total compensation ($USD5.96M) is below average for companies of similar size in the US market ($USD10.88M).
Compensation vs Earnings: Habib's compensation has increased whilst the company is unprofitable.
Experienced Management: XLRN's management team is considered experienced (4.3 years average tenure).
Experienced Board: XLRN's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Acceleron Pharma Inc.'s employee growth, exchange listings and data sources
- Name: Acceleron Pharma Inc.
- Ticker: XLRN
- Exchange: NasdaqGM
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$10.932b
- Shares outstanding: 61.16m
- Website: https://www.acceleronpharma.com
Number of Employees
- Acceleron Pharma Inc.
- 128 Sidney Street
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/20 00:05|
|End of Day Share Price||2021/11/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.